| 56.61 -2.53 (-4.28%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 71.09 | 1-year : | 83.04 |
| Resists | First : | 60.86 | Second : | 71.09 |
| Pivot price | 54.69  |
|||
| Supports | First : | 48.36 |
Second : | 40.63 |
| MAs | MA(5) : | 58.84 |
MA(20) : | 52.38 |
| MA(100) : | 50.22 |
MA(250) : | 58.37 |
|
| MACD | MACD : | 3.7 |
Signal : | 3.3 |
| %K %D | K(14,3) : | 85.3 |
D(3) : | 91.4 |
| RSI | RSI(14): 63.9 |
|||
| 52-week | High : | 76.2 | Low : | 38.59 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LEGN ] has closed below upper band by 39.8%. Bollinger Bands are 86.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 59.53 - 59.88 | 59.88 - 60.15 |
| Low: | 55.1 - 55.56 | 55.56 - 55.9 |
| Close: | 56.01 - 56.68 | 56.68 - 57.19 |
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
Fri, 26 Jul 2024
Legend Biotech (NASDAQ:LEGN) Shares Down 3.6% - MarketBeat
Fri, 26 Jul 2024
US Bancorp DE Has $383,000 Stock Holdings in Legend Biotech Co. (NASDAQ:LEGN) - Defense World
Fri, 26 Jul 2024
Legend Biotech Reports Preliminary H1 2024 Losses - TipRanks
Fri, 26 Jul 2024
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024 - GlobeNewswire
Fri, 26 Jul 2024
Legend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024 - StockTitan
Mon, 22 Jul 2024
Legend Biotech Co. (NASDAQ:LEGN) Forecasted to Earn Q2 2024 Earnings of ($0.34) Per Share - Defense World
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 182 (M) |
| Shares Float | 160 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 49 (%) |
| Shares Short | 11,160 (K) |
| Shares Short P.Month | 13,260 (K) |
| EPS | -2.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.38 |
| Profit Margin | -136 % |
| Operating Margin | -125.5 % |
| Return on Assets (ttm) | -18.3 % |
| Return on Equity (ttm) | -51.3 % |
| Qtrly Rev. Growth | 158.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.88 |
| EBITDA (p.s.) | -2.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -239 (M) |
| Levered Free Cash Flow | -264 (M) |
| PE Ratio | -21.95 |
| PEG Ratio | 0 |
| Price to Book value | 8.85 |
| Price to Sales | 30.1 |
| Price to Cash Flow | -43.26 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|